Anti-infective Agents : Antiviral Agents
OSEBI1 “Sebivo FC tablet” 600 mg/tab
適應症：用於具有病毒複製及活動性肝臟發炎證據的慢性B型肝炎患者的治療。
Usual dose:
Type B viral hepatitis, chronic (adolescents 16 yr and older): 600 mg PO qd.
Dose adjustment:
CrCl 30-49 mL/min: 600 mg PO q48h.
CrCl < 30 mL/min, not requiring hemodialysis: 600 mg PO q72h.
ESRD: 600 mg PO q96h, after hemodialysis.
Precaution: lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination with antiretrovirals; severe acute hepatitis B exacerbations have occurred following the discontinuation of telbivudine; concomitant use with pegylated interferon alfa-2a and other interferons should be avoided; myopathy and myositis have been reported.
Adverse effect:
Common: finding of creatine kinase level, finding of creatine kinase level (grade 3/4), headache, cough, fatigue, influenza.
Serious: lactic acidosis, ALT/SGPT level abnormal (Grade 3/4), AST/SGOT level abnormal (Grade 3/4), hepatomegaly, steatosis of liver, disorder of muscle, rhabdomyolysis.
健保使用規範：同baraclude 0.5 mg。